Page 27 - 2020_08-Haematologica-web

Future research projects in PV and ET
cythemia vera and essential thrombo- cythemia. Ann Hematol. 2015;94(6):911- 918.
45. De Stefano V, Ruggeri M, Cervantes F, et al. High rate of recurrent venous thromboem- bolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists. Leukemia. 2016;30(10):2032-2038.
46. Wille K, Sadjadian P, Becker T, et al. High
risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagu- lation. Ann Hematol. 2019;98(1):93-100.
47. Zwicker JI, Lessen DS, Colucci P, Paranagama D, Grunwald MR. Risk of hemorrhage in patients with poly- cythemia vera exposed to aspirin in com- bination with anticoagulants: results of a prospective, multicenter, observational
cohort study (REVEAL). Blood. 2019;134
(Supplement 1):168.
48. Verstovsek S, De Stefano V, Heidel FH, et
al. US Optum Database study in poly- cythemia vera patients: thromboembolic events (TEs) with hydroxyurea (HU) vs ruxolitinib switch therapy and machine- learning model to predict incidence of TEs and HU failure. Blood. 2019;134 (Supplement 1):1659.
haematologica | 2020; 105(8)
2003